DMAC Stock Price
DiaMedica Therapeutics Inc.
DMAC stock price is $8.01 (+0.25% on the day), giving DiaMedica Therapeutics Inc. a market cap of $430.87M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
DMAC Stock Overview
- Price
- $8.01
- Previous close
- $7.99
- Open
- $7.92
- Market cap
- $430.87M
- P/E ratio
- -13.1
- 52-week range
- $5.25 - $10.42
- 1-year price target
- $15.50
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NSC
- MarketXLS Rank
- 50
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DMAC | $8.01 | +0.3% | 240.27K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get DiaMedica Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW